Leerink reiterates Outperform on OmniAb stock, $10 target By Investing.com

Key event: Leerink reiterates Outperform with a $10.00 price target and OmniAb affirms $25M–$30M guidance. OmniAb reported Q4 fiscal 2025 revenue of $8.4M, down 22.2% YoY, but beat EPS expectations at -$0.11 vs -$0.13 and cut operating expenses by 9.7%. Multiple brokers (Benchmark, Stifel, Truist) maintained Buy ratings; Leerink views Immunovant’s Phase 3 batoclimab failure as not altering OmniAb’s outlook because milestones shift to IMVT-1402, which carries an estimated $100M+ in potential milestones. Balance sheet: cash > debt and current ratio 4.02, but InvestingPro flags rapid cash burn as a risk.

Analysis

OmniAb’s market moves reflect a classic platform vs. partner valuation disconnect: the equity’s upside is concentrated in a small number of binary partner milestones while its downside is governed by cash runway and biotech risk-off. That creates an asymmetric payoff where modest probability of a registrational success for a partner program can meaningfully rerate the platform, but any need to raise equity or loss of partner confidence compresses value quickly.

Second-order beneficiaries include discovery-platform peers and non-dilutive collaborators (licensed programs, CRO/CMO suppliers) who pick up displaced R&D spend if partners pivot away from a failed indication. Conversely, partners with overlapping mechanisms will face accelerated go/no-go decisions as capital is reprioritized; watch partner announcements for amplified volatility across the cohort during the next 3–12 months.

Key risks and catalysts are timing and sequencing: a successful registrational readout on a partner-backed asset is a multi-quarter catalyst that can drive outsized upside, while an equity raise or material partner reprioritization is an immediate negative. Short-term price action will be dominated by headlines and repositioning; medium-term direction depends on cash consumption pace and whether the platform captures milestone payments or sees partner churn over the next 12–24 months.

Key Decisions for Investors

• Directional pair (medium risk): Long OABIW equity (size 1–2% NAV) funded by a matched-dollar short IMVT (size 1–2% NAV). Timeframe 6–18 months. Rationale: hedge platform upside from retained upstream royalties/milestones against continuing downside for the partner; stop-loss at 40% adverse move on the pair and take profits at 2.5x entry if a positive partner readout or material milestone confirmation occurs.
• Option-defined asymmetric (lower cash & tech risk): Buy a 12–30 month OABIW call spread (buy LEAP call / sell a higher strike call to finance ~50–70% of premium). Risk = premium; reward = uncapped to the short strike. Use this to capture rerating into milestone attainment while limiting cash outlay and avoiding immediate dilution risk.
• Event-driven short (opportunistic): Buy 6–12 month IMVT puts (or short IMVT outright) sized 0.5–1% NAV. Timeframe 3–12 months. Rationale: downside remains skewed around additional negative trial or guidance updates; hedge biotech-sector tail risk by pairing with a small long position in a biotech ETF if needed. Take profits on a 35–50% move; cap loss at 30% of premium paid.
• Liquidity/event timing rule: Avoid initiating fresh large exposures within 7–14 trading days of sector-wide risk events (earnings, macro shocks). Reassess after partners publish formal development plans — that announcement is the next high information-content event and should be used to rebalance positions.